Results for rasestumisest translation from Estonian to English

rasestumisest hoidumine
contraception requirements

vajadus hoiduda rasestumisest
need for contraception

rasestumisest tuleb otsekohe teavitada oma arsti.
if you become pregnant, tell your doctor straight away.

partneri rasestumisest tuleb otsekohe teavitada raviarsti
that if his partner becomes pregnant he should inform the treating healthcare professional immediately

neofordexiga toimuva ravi ajal peavad naised hoiduma rasestumisest.
women should avoid pregnancy during neofordex treatment.

fertiilses eas naised peavad ravi ajal rivaroksabaaniga rasestumisest hoiduma.
women of child bearing potential should avoid becoming pregnant during treatment with rivaroxaban.

patsiendid peavad informeerima arsti rasestumisest ravi ajal zimulti’ga.
patients should notify their physician if they become pregnant during treatment with zimulti.

iclusig’iga ravitavad fertiilses eas naised peavad rasestumisest hoiduma.
women of childbearing age being treated with iclusig should avoid becoming pregnant.

fertiilsetele naistele tuleb soovitada tmz kasutamise ajal rasestumisest hoidumiseks tõhusaid rasestumisvastaseid vahendeid.
women of childbearing potential should be advised to use effective contraception to avoid pregnancy while they are receiving tmz.

eriti tuleb rasestumisest hoidumise juhiseid järgida talidomiidi või selle analoogidega samaaegse ravi korral.
in particular, the requirements of the pregnancy prevention programme for combination treatment with thalidomide or its analogues must be followed.

stivarga-ravi ajal tuleb rasestumisest hoiduda, kuna see ravim võib teie sündimata last kahjustada.
avoid becoming pregnant while being treated with stivarga, as this medicine may harm your unborn baby.

fertiilses eas naised peavad ravi ajal kasutama efektiivset rasestumisvastast meetodit ning rasestumisest tuleb otsekohe teavitada arsti.
women of childbearing potential should use contraceptive measures during treatment and should inform their doctor immediately if they become pregnant.

fertiilses eas naised peavad pasopaniib-ravi ajal hoiduma rasestumisest (vt lõik 4.6).
women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with pazopanib (see section 4.6).

fertiilses eas naistele, keda ravitakse dotsetakseeliga, tuleb soovitada raseduse vältimist ja oma raviarsti viivitamatut informeerimist rasestumisest.
women of childbearing age receiving docetaxel should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur.

pegasys’e ja ribaviriini kombinatsiooni kasutavad naispatsiendid või seda kasutavate meespatsientide partnerid peavad pöörama äärmist tähelepanu rasestumisest hoidumisele.
extreme care must be taken to avoid pregnancy in female patients or in partners of male patients taking pegasys in combination with ribavirin.

sarnaselt teiste tsütotoksiliste ravimitega võib topotekaan põhjustada lootekahjustust ning seetõttu tuleb fertiilses eas naisi teavitada, et topotekaanravi ajal tuleb hoiduda rasestumisest.
as with other cytotoxic medicinal products, topotecan may cause foetal harm and therefore women of child bearing potential should be advised to avoid becoming pregnant during therapy with topotecan.

hoiduma rasestumisest ning kasutama usaldusväärseid rasestumisvastaseid vahendeid nii trudexa- ravi ajal kui vähemalt 5 kuu jooksul pärast viimast trudexa- ravi.
you are advised to avoid becoming pregnant and must use adequate contraception while using trudexa and for at least 5 months after the last trudexa treatment.

te peate hoiduma rasestumisest ning kasutama usaldusväärseid rasestumisvastaseid vahendeid nii trudexa-ravi ajal kui vähemalt 5 kuu jooksul pärast viimast trudexa-ravi.
you are advised to avoid becoming pregnant and must use adequate contraception while using trudexa and for at least 5 months after the last trudexa treatment.

rasestuda võivad naised peavad ravi ajal kasutama efektiivset rasestumisvastast meetodit ning rasestumisest tuleb otsekohe teavitada arsti (vt lõik 4.3).
women of childbearing potential must use contraceptive measures during treatment and must inform their doctor immediately if they become pregnant (see section 4.3).

patsiendid peaksid olema teadlikud võimalikust rasestumisest ning kui patsient soovib rasestuda või kui rasestumine on toimunud, tuleb ravi lõpetada (vt lõik 4.6).
patients should be aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occurs, the treatment should be discontinued (see section 4.6).